We’re calling on global leaders to uphold diagnostics and equitable access to testing within their commitments to support sustainable recovery from COVID-19.
Join usData since 2015
71
clinical trials
undertaken
11
WHO recommendations supported
6,000+
health workers trained
32,500+
patients enrolled in studies
50m+
FIND-supported
products procured
3,000+
laboratories & testing
sites strengthened
MEDIA ADVISORY: Current testing tools uncompromised by new COVID-19 variant of concern Omicron (B.1.1.529)
ReadOn World Children’s Day, FIND welcomes improved access to childhood diagnosis of tuberculosis
ReadUS$3.9 million investment in diagnostic network optimization enables OptiDx partnership to scale up activities across 15 countries
ReadMeet Sabir. He is 14 years old and lives in Surat, India. He loves studying and competed in the national Science Olympiad. He found out he had TB only after learning about the disease during a school visit by doctors.
Read
Zaza is a social worker at Imedi HRS in Batumi, Georgia. With a lab specialist, Zaza does community outreach work conducting mobile counseling and screening for hepatitis C and other infectious diseases, using a lab-in-a van.
Read
This is Jennifer from the Research Institute for Tropical Medicine (RITM) in the Philippines, leading a workshop in Addis Ababa, Ethiopia, on quality testing for malaria rapid tests.
Read
Today we mark World Hepatitis Day, taking the opportunity this year to reflect on the successful completion of our 3-year Hepatitis C Elimination through Access to Diagnostics (HEAD-Start) project that has been supported by Unitaid. HEAD-Start accelerated the development of 9 new diagnostic technologies for hepatitis C, and has enabled us to get closer to the global goal of reaching hepatitis elimination by 2030 – 10-year projections of the impact…
Read moretest
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Aliquam aspernatur, at blanditiis culpa ea et expedita iure iusto laboriosam laborum maiores minima modi nostrum nulla officia quibusdam repellendus suscipit voluptatibus!
test tes test test test ttdfs
R&D
Clinical trials
Access
Geneva, Switzerland (HQ)
Hanoi, Viet Nam
New Delhi, India
Cape Town, South Africa
Nairobi, Kenya
